Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure
- PMID: 31092017
- DOI: 10.1080/15569527.2019.1616749
Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure
Abstract
Objective: To evaluate short term changes in anterior chamber depth (ACD), central corneal thickness (CCT), intraocular pressure (IOP), and corneal endothelial cell density (ECD) after intravitreal anti-vascular endothelial growth factor (VEGF) injections. Materials and methods: A total of 100 eyes from 100 patients, who were naive for intravitreal injection treatment, were included in this retrospective study. Patients who received only a single type of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, or aflibercept) for two consecutive months were examined. ACD, CCT, IOP, and ECD measurements were taken at pre-injection and one month after the first and second injections and were compared. Results: The mean corneal ECD for all eyes and phakic eyes was significantly lower one month after the first (p = 0.041 and p = 0.047, respectively) and second injections (p = 0.013 and p = 0.034, respectively) compared to the values at pre-injection levels. Similarly, the mean ACD of all eyes and phakic eyes was significantly lower one month after the first (p < 0.001 and p < 0.001, respectively) and second injections (p < 0.001 and p < 0.001, respectively) compared to the values at pre-injection levels. However, there was no significant difference in pseudophakic eyes one month after the first and second injections (ECD, p = 0.28 and p = 0.23; ACD, p = 0.75 and p = 0.71, respectively). There was no significant change in IOP and CCT values at pre-injection and one month after the first and second injections for all eyes and for both the phakic and pseudophakic eyes. Discussion: After the anti-VEGF injections, IOP and CCT values were not significantly changed and were similar in all eyes and phakic eyes; however, in these groups, there was a small but statistically significant decrease in ACD and ECD. On the contrary, there was no significant difference in pseudophakic eyes. Clinicians performing intravitreal injections must be aware of these associations for a better understanding of ACD and ECD changes in phakic eyes.
Keywords: Anterior chamber depth; anti-VEGF; central corneal thickness; endothelial cell density; intraocular pressure.
Similar articles
-
Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.Curr Eye Res. 2014 Oct;39(10):989-93. doi: 10.3109/02713683.2014.888452. Epub 2014 Mar 3. Curr Eye Res. 2014. PMID: 24588314 Clinical Trial.
-
Evaluating short-term corneal endothelial alterations post-intravitreal Anti-VEGF injections in treatment naïve eyes.Rom J Ophthalmol. 2025 Apr-Jun;69(2):212-218. doi: 10.22336/rjo.2025.34. Rom J Ophthalmol. 2025. PMID: 40698111 Free PMC article.
-
The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.Int Ophthalmol. 2016 Oct;36(5):665-70. doi: 10.1007/s10792-016-0171-1. Epub 2016 Jan 16. Int Ophthalmol. 2016. PMID: 26780098
-
Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.Wien Klin Wochenschr. 2017 May;129(9-10):351-357. doi: 10.1007/s00508-016-1055-0. Epub 2016 Aug 22. Wien Klin Wochenschr. 2017. PMID: 27550436 Review.
-
Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.Br J Ophthalmol. 2019 Apr;103(4):442-451. doi: 10.1136/bjophthalmol-2018-312691. Epub 2018 Nov 8. Br J Ophthalmol. 2019. PMID: 30409915
Cited by
-
Prophylaxis with intraocular pressure lowering medication and glaucomatous progression in patients receiving intravitreal anti-VEGF therapy.Int J Ophthalmol. 2022 Oct 18;15(10):1611-1618. doi: 10.18240/ijo.2022.10.08. eCollection 2022. Int J Ophthalmol. 2022. PMID: 36262842 Free PMC article.
-
Effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion-induced macular edema.Front Med (Lausanne). 2025 Jun 25;12:1595543. doi: 10.3389/fmed.2025.1595543. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40636373 Free PMC article.
-
Corneal Endothelial Cell Changes Associated with Multiple Intravitreal Injections.J Curr Ophthalmol. 2025 Feb 6;36(3):279-283. doi: 10.4103/joco.joco_26_23. eCollection 2024 Jul-Sep. J Curr Ophthalmol. 2025. PMID: 40557412 Free PMC article.
-
Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose.Ther Adv Ophthalmol. 2020 Aug 27;12:2515841420950857. doi: 10.1177/2515841420950857. eCollection 2020 Jan-Dec. Ther Adv Ophthalmol. 2020. PMID: 32923942 Free PMC article.
-
Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration.J Ophthalmol. 2020 Jun 9;2020:4928905. doi: 10.1155/2020/4928905. eCollection 2020. J Ophthalmol. 2020. PMID: 32587759 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources